DOI: 10.21276/ajptr
Mon, 25 Mar 2019

A Brief Review on Obeticholic Acid: the First Farnesoid X Receptor Agonist

Sripada Ramam1*, Kuppili Venkata Sai Kiran1, Sathish Kalluri1, Narise Anusha1, Bonam Jyothi1, Magharla Dasaratha Dhana Raju1

1. Department of Pharmacy practice, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India 533296.


Obeticholic acid is a pharmaceutical agent under development used especially to treat liver and gastrointestinal disorders. Its chemical structure is 6 α-ethyl-chenodeoxycholic acid (Figure1). It is a semi synthetic bile acid analogue. In human drug studies, Obeticholic acid is the first farnesoid X receptor agonist and at present, this drug is under phase-II and phase-III clinical trials. Various clinical studies were conducted by using this drug Obeticholic acid to assess the safety and efficacy. In this article, we reviewed the different studies available on Obeticholic acid and its therapeutic use in diseases like non alcoholic steatohepatitis, primary biliary cirrhosis, bile acid malabsorption and portal hypertension.

Keywords: Obeticholic acid, 6 α-ethyl-chenodeoxycholic acid, Farnesoid X receptor agonist.

[PDF]   Viewed: 1380   Downloaded: 192
  • Call for paper

    American Journal of PharmTech Research (AJPTR) is a peer-reviewed, bimonthly official international journal allowing access to abstracts and full-text.



  • Email & SMS Alerts

    Email/SMS alert system is one of the key features and gives update information about the submitted manuscript.


  • Article Statastics

    American Journal of PharmTech Research (AJPTR) provides unique facility for authors to know popularity of articles on basis of numbers of PDF download and views. It will display in tabulated format.

  • Online Submission

    American Journal of PharmTech Research (AJPTR) is one of the International open access journal devoted to various disciplines in science and technology.


web counter
web counter